Search Bar & Filters
Found 34 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of two drugs, inebilizumab and blinatumomab, in adults with active and treatment-resistant autoimmune diseases, including systemic lupus erythematosus SLE with nephritis and rheumatoid arthritis RA. This Phase 2 trial includes several subprotocols to study these medications in different patient groups and disease conditions. Participants may receive inebilizumab through intravenous infusions in either three or four doses, or blinatumomab via subcutaneous injections at low, medium, or high doses. The trial includes parts where doses are determined based on earlier results. The treatments are studied in subgroups of patients with SLE with or without nephritis and in patients with active refractory RA. Throughout the study, participants will be monitored for treatment-emergent adverse events and serious adverse events up to 52 weeks. Various clinical measures for kidney response, disease remission, and disease activity scores will be assessed at multiple time points. Safety, drug levels, antibody formation, and disease activity changes will be tracked regularly, with a total study duration extending up to 52 weeks for outcome evaluations.
Actively Recruiting
Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.
Actively Recruiting
Researchers are evaluating the real-world effectiveness of angiotensin receptor-neprilysin inhibitor ARNi therapy compared to antihypertensive monotherapy in lowering blood pressure among adults with hypertension in the United Arab Emirates. The study focuses on patients diagnosed with hypertension and aims to see how these treatments impact blood pressure control in everyday clinical settings. The study includes two groups one group starts or switches to ARNi treatment sacubitrilvalsartan, and the other begins antihypertensive monotherapy with either an ACE inhibitor, an ARB, or a calcium channel blocker. Patients will be observed as they receive these therapies according to their physicians direction. Participants will have their blood pressure measured at the start and during follow-up visits, with primary measurement focused on the change in mean sitting systolic blood pressure from baseline to week 4. Additional measures include diastolic blood pressure, pulse pressure, and the proportion of patients reaching target blood pressure at weeks 4 and 12. The study will continue until August 2027, with assessments occurring at these defined timepoints to monitor treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of oral Apabetalone combined with background dapagliflozin treatment for up to 12 weeks in adults with type 2 diabetes mellitus T2DM who have experienced probable or confirmed COVID-19 infection. Participants must have symptoms of Long COVID lasting at least 2 months within 3 months from the start of COVID-19, which cannot be explained by other diagnoses. This phase II, open-label multicentre trial aims to better understand treatment options for this group of patients. Participants will take oral Apabetalone 100 mg capsules twice daily with meals while continuing their daily dapagliflozin 10 mg therapy for diabetes. The study involves seven in-person clinic visits where data will be collected to assess the treatments effects. After screening and consent, eligible participants begin Apabetalone treatment on Day 1 and continue it at home under study supervision. During the trial, participants will undergo various assessments including symptom evaluations and functional status tools related to Long COVID. The primary outcome is the patient acceptable symptom state at 90 days. Secondary measures include fatigue, dyspnea, and post-exertional malaise assessments. Safety and adherence will be monitored throughout, with the total study duration covering treatment and follow-up visits over approximately 12 weeks.
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.
Actively Recruiting
Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.
Actively Recruiting
Researchers are evaluating dapirolizumab pegol DZP as an additional treatment alongside standard care medications for people with moderately to severely active systemic lupus erythematosus SLE. The study aims to determine if DZP can provide meaningful long-term improvement in disease activity compared to placebo. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by UCB Biopharma SRL. Participants are randomly assigned to receive either dapirolizumab pegol or a placebo throughout the treatment period. Both groups continue their standard of care medication during the trial. The treatment is administered at prespecified time points during the study, which lasts for 48 weeks. The study monitors disease activity and safety outcomes during this time. During the study, participants will attend regular visits to assess disease activity using measures such as the British Isles Lupus Assessment Group Disease Activity Index BILAG 2004 and the Systemic Lupus Erythematosus Disease Activity Index 2000 SLEDAI-2K. Researchers will also evaluate fatigue, glucocorticoid dose reduction, and record any treatment-emergent adverse events. Safety follow-up continues up to 54 weeks. Overall participation lasts nearly a year, including treatment and follow-up assessments.
Actively Recruiting
Researchers are comparing the accuracy of two denture impression methods for adults who have lost all their teeth. This study evaluates whether digital intraoral scanning matches the accuracy of conventional border-molded impressions in capturing mouth shapes, including movable gum areas. The study also examines if repeated digital scans are consistent when taken multiple times on the same patient. Participants will have their fully edentulous upper andor lower jaw scanned three times using a TRIOS 5 intraoral scanner following a structured sequence to capture the full arch including the palate and ridge slopes. After digital scans, each participant will also receive a conventional impression using a custom tray and border molding technique. Both procedures occur during two visits at Dubai Dental Hospital. Participants will provide informed consent and attend two study visits where scans and impressions are taken. Researchers will analyze the accuracy by measuring the difference between digital and conventional impressions and assess the precision of repeated digital scans. The main outcomes include the mean deviation between the two methods per arch and precision within repeated digital scans. Secondary outcomes compare differences between upper and lower jaws and between fixed and movable gum areas. Participation lasts about one week for outcome assessment.
Actively Recruiting
Researchers are gathering real-world data on the outcomes of patients with perimembranous ventricular septal defects PmVSD, a heart condition, who have undergone transcatheter closure using various device occluders. This international, multicenter, non-interventional, observational study aims to evaluate how well these devices work and their safety when used in both children and adults. The study focuses on patients treated with devices either specifically designed for PmVSD closure or used off-label. Participants in this study have had their PmVSD closed using commercially available occluder devices through a transcatheter procedure. The devices are placed without open-heart surgery to close the defect. The study observes patients who have already undergone this procedure and collects follow-up data according to each hospitals usual practice. The study does not intervene but monitors how these devices perform over time. Participants will be followed for up to 60 months after their procedure to assess clinical success, technical success, closure success, and any device-related complications. Researchers will also evaluate functional outcomes and quality of life for up to 48 months post-procedure. Data collection includes clinical events from the implant attempt through the follow-up period, and safety is monitored by tracking adverse events. The total duration of participation depends on the timing of the procedure and follow-up visits according to local protocols.
1-10 of 34
1